1.Wong WW; Minuk GY. A cross-sectional seroepidemiologic survey of chronic hepatitis B virus infections in Southeast Asian immigrants residing in a Canadian urban centre. Clin Invest Med 1994 17:443-7
2.Sweet LE; Brown MG; Lee SH; Liston RM; MacDonald MA; Forward KR. Hepatitis B prenatal screening survey, Nova Scotia, 1990-1991. Can J Public Health 1993 84:279-82
3.Chernesky MA; Blajchman MA; Castriciano S; Basbaum J; Spivak C; Mahony JB. Analysis of a pregnancy-screening and neonatal-immunization program for hepatitis B in Hamilton, Ontario, Canada, 1977-1988. J Med Virol 1991 35:50-4
4.Delage G; Montplaisir S; Remy-Prince S; Pierri E. Prevalence of hepatitis B virus infection in pregnant women in the Montreal area. Can Med Assoc J 1986 134:897-901
5.Minuk GY; Nicolle LE; Postl B; Waggoner JG; Hoofnagle JH. Hepatitis virus infection in an isolated Canadian Inuit (Eskimo) population. J Med Virol 1982;10:255-64
6.Baikie M; Ratnam S; Bryant DG; Jong M; Bokhout. Epidemiologic features of hepatitis B virus infection in Northern Labrador. Can Med Assoc J 1989 141:791-5
7.Fattovich G, Giustina G; Schalm SW; Hadziyannis S; Sanchez-Tapias J; Almasio P; et al. Christensen E;. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. Hepatology. 1995;21:77-82
8.Lok AS, Lai CL. A longitudinal follow-up of asymptomatic hepatitis B surface antigen-positive Chinese children. Hepatology 1988 8:1130-3
9.Gupta S, Govindarajan S, Fong TL, Redeker AG. Spontaneous reactivation in chronic hepatitis B patterns and natural history. J Clin Gastroenterol 1990 12:562-8
10.Fattovich G, Brollo L, Alberti A, Realdi G, Pontisso P et al. Spontaneous reactivation of hepatitis B virus infection in patients with chronic type B hepatitis. Liver 1990 10:141-6.
11.Lok AS, Lai CL. Acute exacerbations in Chinese patients with chronic hepatitis B virus infection. Incidence, predisposing factors and etiology. J Hepatol 1990 10:29-34.
12.Lok AS, Lai CL, Wu PC, Leung EK, Lam T. Spontaneous hepatitis B e antigen to antibody serconversion and reversion in Chinese patients with chronic hepatitis B virus infection. Gastroenterology 1987 92:1839-43
13.Fattovich G, Rigge M, Brollo L, Pontisso P, Noventa F, Guido M et al. Clinical, virologic and histologic outcome following serconversion from HBeAg to anti-HBe in chronic hepatitis type B. Hepatology 1986 6:167-72
14.de Franchis R, Meucci G, Vecchi M, Tatarella M,colombo M, Del Ninno, Rumi MG et al. The natural history of symptomatic hepatitis B surface antigen carriers. Ann Int Med 1993 118:191-4
15.Fattovich G, Guistina G, Sanchez-Tapias J, Quero C, Mas A, Olivotto PG et al. Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. European Concerted Action on Viral Hepatitis (EUROHEP). Am J Gastroenterol 1998;93:896-900.
16.Koh KC, Lee HS, Kim CY, Universal emergence of precore mutant hepatitis B virus along with seroconversion to anti-HBe irrespective of subsequent activity of chronic hepatitis B. Korean J intern Med 1994 9: 61-6
17.Realdi G, Fattovich G, Hadziyannis S, Schalm SW, Almasio P, Sanchez-Tapias J et al. Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. The investigators of the European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol 1994 21:656-66
18.de Jongh FE; Janssen HL; de Man RA; Hop WC, Schalm SW; van Blankenstein M. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992;103:1630-5
19.Fattovich G, Brollo L, Guistina G, Noventa F, Pontisso P Alberti A et al. Natural history and prognostic factors for chronic hepatitis type B. Gut 1991 32:194-8
20.Beasley RP, Hwang LY; Lin CC; Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22,707 men in Taiwan. Lancet. 1981;2(8256):1129-33.
21.Lai CL, Chien RN; Leung NW; Chang TT; Guan R; Tai DI, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med. 1998;339:61-8.
22.Heathcote J, Schalm S, Ciancara J, Farrell G, Feinman V, Sherman M et al. Lamivudine and Intron A combination treatment in chronic hepatitis B infection. Hepatology 1998, 28 Suppl:43.
23.Schiff E, Karayalcin S, Grimm I, Perrillo R Dinestag J, Hasa P et al. A placbo-controlled study of lamivudine and interferon alpha 2 b in patients with chronic hepatitis B who previously failed interferon therapy. Hepatology 1998 28 Suppl:43.
24.Allen MI; Deslauriers M; Andrews CW; Tipples GA; Walters KA; Tyrrell DL; et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998 27:1670-7
25.Di Bisceglie AM, Fong TL, Fried MW, Swain MG, Baker B, Korenman J et al. A randomized controlled trial of recombinant alpha interferon therapy for chronic hepatitis B. Am J Gastroenterology 1993 88:1887-92
26.Lok AS, Lai CL, Wu PC, Leung EK. Long-term follow-up in a randomized controlled trial of recombinant interferon alpha-2 in Chinese patients with chronic hepatitis B infection. Lancet 1988 2:298-302
27.Lai CL, Lok AS, Lin HJ, Wu PC, Yeoh EK, Yeung CY. Placebo-controlled trial of recombinant alpha-2 interferon in Chinese HBsAg-carrier children. Lancet 1987 2:877-80
28.Krogsgaard K; Bindslev N; Christensen E; Craxi A; Schlichting P; Schalm S et al. The treatment effect of alpha interferon in chronic hepatitis B is independent of pre-treatment variables. Results based on individual patient data from 10 clinical controlled trials. European Concerted Action on Viral Hepatitis (Eurohep). J Hepatol 1994 Oct;21(4):646-55
29.Thomas HC; Lok AS; Carreno V; Farrell G; Tanno H; Perez V; et al. Comparative study of three doses of interferon-alpha 2a in chronic active hepatitis B. The International Hepatitis Trial Group. J Viral Hepat 1994;1(2):139-48
30.Brook MG; McDonald JA; Karayiannis P; Caruso L, Forster G; Harris JR; Thomas HC. Randomized controlled trial of interferon alfa 2A (rbe) (Roferon-A) for the treatment of chronic hepatitis B virus (HBV) infection: factors that influence response. Gut 1989;30:1116-22
31.Wong DK; Yim C; Naylor CD; Chen E; Sherman M; Vas S et al. Interferon alfa treatment of chronic hepatitis B: randomized trial in a predominantly homosexual male population. Gastroenterology 1995;108:165-71
32.Brook MG; Karayiannis P; Thomas HC. Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors. Hepatology 1989;10:761-3
33.Lok AS, Ghany MG, Watson G, Ayola B. Predictive value of aminotransferase and hepatitis B virus DNA levels on response to interferon therapy for chronic hepatitis B. J Viral Hepat 1998 5:171-8
34.Fattovich G, McIntyre G; Thursz M; Colman K; Giuliano G; Alberti A et al. Hepatitis B virus precore/core variation and interferon therapy. Hepatology. 1995;22:1355-62.
35.Tassopoulos NC; Volpes R; Pastore G; Heathcote J; Buti M; Goldin RD et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B.Lamivudine Precore Mutant Study Group. Hepatology 1999 29:889-96
36.Picardi M; Selleri C; De Rosa G; Raiola A; Pezzullo L; Rotoli B. Lamivudine treatment for chronic replicative hepatitis B virus infection after allogeneic bone marrow transplantation. Bone Marrow Transplant 199;21:1267-9
37.Brind AM, et al. Nucleoside analogue therapy in fibrosing cholestatic hepatitis--a case report in an HBsAg positive renal transplant recipient. Liver. 1998;18:134-9.
38.Lok AS, Lindsay I, Scheuer PJ, Thomas HC. Clinical and histological features of delta infection in chronic hepatitis B virus carriers. J Clin Pathol 1985 38:530-3
39.Farci P; Mandas A; Coiana A; Lai ME; Desmet V, Van Eyken P et al. Treatment of chronic hepatitis D with interferon alfa-2a. N Engl J Med 1994;330:88-94
40.Perrillo R; Tamburro C; Regenstein F; Balart L Bodenheimer H; Silva M et al. Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. Gastroenterology 1995;109:908-16
41.Lin CY Treatment of hepatitis B virus-associated membranous nephropathy with recombinant alpha-interferon. Kidney Int 1995;47:225-30.
42.Conjeevaram HS; Hoofnagle JH; Austin HA; Park Y, Fried MW; Di Bisceglie AM. Long-term outcome of hepatitis B virus-related glomerulonephritis after therapy with interferon alfa. Gastroenterology 1995;109:540-6
43.Bortolotti F, Faggion S, Con P. Natural history of chronic viral hepatitis in childhood. Acta Gastroenterol Belg 1998 61:198-201.
44.Sokal EM; Conjeevaram HS; Roberts EA; Alvarez F, Bern EM; Goyens P et al. Interferon alfa therapy for chronic hepatitis B in children: a multinational randomized controlled trial. Gastroenterology 1998;114:988-95
45.Robertson B; Myers G; Howard C; Brettin T; Bukh J; Gaschen B et al. Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. International Committee on Virus Taxonomy. Arch Virol 1998;143:2493-503
46.Bernier L, Willems B, Delage G, Murphy DG. Indentification of numerous hepatitis C virus genotypes in Montreal, Canada. J Clin Microbiol 1996 34:2815-8
47.Murphy DG, Willems B, Delage G, Fenyves D, Huet PM, Marleau D et al. Hepatitis C virus genotypes in patients and blood donors. Can Commun Dis Rep 1995 21:129-32
48.Altamirano M, Delaney A, Wong A, Maronstenmaki J, Pi D. Identification of hepatitis C virus genotypes among hospitalized patients in British Columbia, Canada. J Infect Dis 1995 171:1034-8
49.Andonov A, Chaudhari RK. Genotyping of Canadian hepatitis C virus isolates by PCR. J Clin Microbiol 1994:2031-4.
50.Tong MJ; el-Farra NS; Reikes AR; Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995;332:1463-6
51.Pol S; Fontaine H; Carnot F; Zylberberg H, Berthelot P; Brechot C; Nalpas B. Predictive factors for development of cirrhosis in parenterally acquired chronic hepatitis C: a comparison between immunocompetent and immunocompromised patients. J Hepatol 1998;29:12-9
52.Niederau C, Lange S; Heintges T; Erhardt A; Buschkamp M; Hurter D et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology. 1998;28:1687-95.
53.Wiley TE; McCarthy M; Breidi L; McCarthy M, Layden TJ. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology 1998;28:805-9
54.Pol S; Lamothe B; Thi NT; Thiers V; Carnot F, Zylberberg H et al.
Retrospective analysis of the impact of HIV infection and alcohol use on
chronic hepatitis C in a large cohort of drug users. J Hepatol 1998;28:945-50
55.Pessione F; Degos F; Marcellin P; Duchatelle V, Njapoum C; Martinot-Peignoux
M et al. Effect of alcohol consumption on serum hepatitis C virus RNA and
histological lesions in chronic hepatitis C. Hepatology 1998;27:1717-22 56.Yano M; Kumada H; Kage M; Ikeda K; Shimamatsu K; Inoue O et al. The
long-term pathological evolution of chronic hepatitis C. Hepatology 1996
23:1334-40 57.Roudot-Thoraval F; Bastie A; Pawlotsky JM Dhumeaux D. Epidemiological
factors affecting the severity of hepatitis C virus-related liver disease:
a French survey of 6,664 patients. The Study Group for the Prevalence and
the Epidemiology of Hepatitis C Virus. Hepatology 1997;26:485-90 58.Sobesky R; Mathurin P; Charlotte F; Moussalli J Olivi M; Vidaud M
et al. Modeling the impact of interferon alfa treatment on liver fibrosis
progression in chronic hepatitis C: a dynamic view. The Multivirc Group.
Gastroenterology 1999;116:378-86 59.Kenny-Walsh E. Clinical outcomes after hepatitis C infection from
contaminated anti-D immune globulin. Irish Hepatology Research Group. N
Engl J Med. 1999;340:1228-33. 60.Mathurin P; Moussalli J; Cadranel JF; Thibault V Charlotte F; Dumouchel
P, et al Slow progression rate of fibrosis in hepatitis C virus patients
with persistently normal alanine transaminase activity. Hepatology 1998;27:868-72 61.Poynard T; Bedossa P; Opolon P. Natural history of liver fibrosis
progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR,
CLINIVIR, and DOSVIRC groups. Lancet 1997 349:825-32 62.Fattovich G, Giustina G; Degos F; Tremolada F; Diodati G; Almasio
P et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective
follow-up study of 384 patients. Gastroenterology. 1997;112:463-72. 63.Piazza M,. Sagliocca L; Tosone G; Guadagnino V; Stazi MA; Orlando
R et al. Sexual transmission of the hepatitis C virus and efficacy of prophylaxis
with intramuscular immune serum globulin. A randomized controlled trial.
Arch Intern Med. 1997;157:1537-44. 64.Kao JH, Liu CJ; Chen PJ; Chen W; Hsiang SC; Lai MY; Chen DS. Interspousal
transmission of GB virus-C/hepatitis G virus: a comparison with hepatitis
C virus. J Med Virol. 1997;53:348-53. 65.Comandini UV; Tossini G; Longo MA; Ferri F; Cuzzi G; Noto P Sporadic
hepatitis C virus infection: a case-control study of transmission routes
in a selected hospital sample of the general population in Italy. Scand
J Infect Dis 1998;30(1):11-5 66.Eyster ME, Alter HJ; Aledort LM; Quan S; Hatzakis A; Goedert JJ.
Heterosexual co-transmission of hepatitis C virus (HCV) and human immunodeficiency
virus (HIV).: Ann Intern Med. 1991;115:764-8. 67.Thomas DL, Zenilman JM; Alter HJ; Shih JW; Galai N; Carella AV; Quinn
TC. Hepatitis C, hepatitis B, and human immunodeficiency virus infections
among non-intravenous drug-using patients attending clinics for sexually
transmitted diseases. J Infect Dis. 1994;169:990-5. 68.Akahane Y Kojima M; Sugai Y; Sakamoto M; Miyazaki Y; Tanaka T; et
al. Hepatitis C virus infection in spouses of patients with type C chronic
liver disease. Ann Intern Med. 1994;120:748-52. 69.Caporaso N; Ascione A; Stroffolini T. Spread of hepatitis C virus
infection within families. Investigators of an Italian Multicenter Group.
J Viral Hepat 1998 5:67-72 70.Ohto H, Terazawa S; Sasaki N; Sasaki N; Hino K; Ishiwata C et al.
Transmission of hepatitis C virus from mothers to infants. The Vertical
Transmission of Hepatitis C Virus Collaborative Study Group. N Engl J Med.
19947;330:744-50. 71.Zanetti AR, Tanzi E; Romano L; Zuin G; Minola E; Vecchi L; Principi
N. A prospective study on mother-to-infant transmission of hepatitis C
virus. Intervirology. 1998;41:208-12. 72.Meisel H, Reip A; Faltus B; Lu M; Porst H; Wiese M; et al. Transmission
of hepatitis C virus to children and husbands by women infected with contaminated
anti-D immunoglobulin. Lancet. 1995;345(8959):1209-11. 73.Thomas DL, Villano SA; Riester KA; Hershow R; Mofenson LM; Landesman
SH et al. Perinatal transmission of hepatitis C virus from human immunodeficiency
virus type 1-infected mothers. Women and Infants Transmission Study. J
Infect Dis. 1998;177:1480-8. 74.Marcellin P; Boyer N; Gervais A; Martinot M, Pouteau M; Castelnau
C et al. Long-term histologic improvement and loss of detectable intrahepatic
HCV RNA in patients with chronic hepatitis C and sustained response to
interferon-alpha therapy. Ann Intern Med 1997;127:875-81 75.Reichard O, Norkrans G; Fryden A; Braconier JH; Sonnerborg A; Weiland
O. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b
with and without ribavirin for chronic hepatitis C. The Swedish Study Group.
Lancet. 1998;351(9096):83-7. 76.McHutchison JG, Gordon SC; Schiff ER; Shiffman ML; Lee WM; Rustgi
VK et al. Interferon alfa-2b alone or in combination with ribavirin as
initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy
Group. N Engl J Med. 1998;339:1485-92. 77.Poynard T, Marcellin P; Lee SS; Niederau C; Minuk GS; Ideo G et al.
Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for
24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment
of chronic infection with hepatitis C virus. International Hepatitis Interventional
Therapy Group. Lancet. 1998 ;352(9138):1426-32. 78.Laursen AL, Scheibel E, Ingerslev J, Clausen NC, Wantzin P, Ostergaard
L et al. Alpha interferon therapyin Danish hemophliac patients with chronic
hepatitis C: results of a randomized controlled open label study comparing
two different maintenance regimens following standard interferon alpha
2b treatment. Haemophilia 1998 4:25-32. 79.Rumi MG, Santagostino E, Morfini M, Gringeri A, Tagariello G, Chistolini
A et al. A multicenter controlled randomized open label trial of interferon
alpha 2b treatment of anti-human immunodeficiency virus-negative hemophiliac
patients with chronic hepatitis C. Hepatitis Study Group of the Italian
Hemophilia Centers. Blood 1997 89:3529-33
81.Heathcote EJ; Keeffe EB; Lee SS; Feinman SV; Tong MJ Reddy KR et
al. Re-treatment of chronic hepatitis C with consensus interferon. Hepatology
1998;27:1136-43 82.Garcia-Monzon C, et al. Chronic hepatitis C in children: a clinical
and immunohistochemical comparative study with adult patients. Hepatology.
1998;28:1696-701. 83.Iorio R; Pensati P; Porzio S; Fariello I; Guida S; Vegnente A. Lymphoblastoid
interferon alfa treatment in chronic hepatitis C. Arch Dis Child. 1996;74:152-6. 84.Bortolotti F, Giacchino R; Vajro P; Barbera C; Crivellaro C; Alberti
A; et al. Recombinant interferon-alfa therapy in children with chronic
hepatitis C. Hepatology. 1995;22:1623-7. 85.Viladomiu L; Genesca J; Esteban JI; Allende H, Gonzalez A; Lopez-Talavera
JC et al. Interferon-alpha in acute posttransfusion hepatitis C: a randomized,
controlled trial. Hepatology 1992;15:767-9 86.Hwang SJ; Lee SD; Chan CY; Lu RH; Lo KJ. A randomized controlled
trial of recombinant interferon alpha-2b in the treatment of Chinese patients
with acute post-transfusion hepatitis C. J Hepatol. 1994;21:831-6. 87.Lampertico P, Rumi M; Romeo R; Craxi A; Soffredini R; Biassoni D;
Colombo M. A multicenter randomized controlled trial of recombinant interferon-alpha
2b in patients with acute transfusion-associated hepatitis C. Hepatology.
1994;19:19-22. 88.Crespo J, Lozano JL, de la Cruz F, Rodrigo L, Rodriguez M, San Miguel
G et a;. Prevalence and significance of hepatitis C viremia in chronic
active hepatitis B. Am J Gastroenterol 1994;89:1147-51 89.Chan CY; Lee SD; Wu JC; Hwang SJ; Wang YJ; Huang YS, Lo KJ. Superinfection
with hepatitis C virus in patients with symptomatic chronic hepatitis B.
Scand J Infect Dis 1991;23:421-4 90.Sato S; Fujiyama S; Tanaka M; Yamasaki K; Kuramoto I, Kawano S et
al. Coinfection of hepatitis C virus in patients with chronic hepatitis
B infection. J Hepatol 1994;21:159-66 91.Serfaty L, Aumaitre H; Chazouilleres O; Bonnand AM; Rosmorduc O;
Poupon RE; Poupon R. Determinants of outcome of compensated hepatitis C
virus-related cirrhosis. Hepatology. 1998;27:1435-40. 92.Fong TL; Di Bisceglie AM; Waggoner JG; Banks SM, Hoofnagle JH. The
significance of antibody to hepatitis C virus in patients with chronic
hepatitis B. Hepatology 1991;14:64-7 93.Benvengu L, Fattovich G, Noventa F, Tremolada F, Chemello L, Cecchetto
A, ,Alberti A. Concurrent hepatitis B and C virus infection and risk of
hepatocellular carcinoma in cirrhosis. Cancer 1994 74:2442-8 94.Pontisso P, Ruvoletta MG, Fattovich G, Chemello L, Gallorini, F,
Ruol A, Alberti A. Clinical and virological profiles in patients with multiple
hepatitis virus infections. Gastroenterology 1993 105:1529-33 95.Zarski JP; Bohn B; Bastie A; Pawlotsky JM; Baud M, Bost-Bezeaux F
et al. Buffet C; Dhumeaux D. Characteristics of patients with dual infection
by hepatitis B and C viruses. J Hepatol 1998;28:27-33 96.Chiba T; Matsuzaki Y; Abei M; Shoda J; Aikawa T, Tanaka N; Osuga
T. Multivariate analysis of risk factors for hepatocellular carcinoma in
patients with hepatitis C virus-related liver cirrhosis. J Gastroenterol
1996;31:552-8 97.Weltman MD; Brotodihardjo A; Crewe EB; Farrell GC, Bilous M; Grierson
JM; Liddle C. Coinfection with hepatitis B and C or B, C and delta viruses
results in severe chronic liver disease and responds poorly to interferon-alpha
treatment. J Viral Hepat 1995;2:39-45 98.Hess G; Rossol S; Voth R; Gerken G; Ramadori G, Drees N; Meyer zum
Buschenfelde KH. Treatment of patients with chronic type B hepatitis and
concurrent human immunodeficiency virus infection with a combination of
interferon alpha and azidothymidine: a pilot study. Digestion 1989;43:56-9 99.Macias J, Pineda JA, Leal MA, Garcia-Pesquera F, DelgadoJ, Gallardo
JA et al. Influence of hepatitis C infection on the mortality of antiretroviral-treated
patients with HIV disease. Eur J Clin Microbiol Infect Dis 1998 17:167-70. 100.Ghany MG, Leissinger C, Lagier R, Sanchez-Pescador R, Lok AS. Effect
of human immunodeficiency virus infection on hepatitis C virus infection
in hemophiliacs. Dig Dis Sci 1996 41:1265-72. 101.Soriano V; Garcia-Samaniego J; Bravo R; Castro A Odriozola PM; Gonzalez
J et al. Efficacy and safety of alpha-interferon treatment for chronic
hepatitis C in HIV-infected patients. HIV-Hepatitis Spanish Study Group.
J Infect 1995 31:9-13 102.Mauss S; Klinker H; Ulmer A; Willers R; Weissbrich B Albrecht H
et al. Response to treatment of chronic hepatitis C with interferon alpha
in patients infected with HIV-1 is associated with higher CD4+ cell count.
Infection 1998;26:16-9 103.Mauss S; Heintges T; Adams O; Albrecht H; Niederau C, Jablonowski
H. Treatment of chronic hepatitis C with interferon-alpha in patients infected
with the human immunodeficiency virus. Hepatogastroenterology 1995;42:528-34 104.Boyer N; Marcellin P; Degott C; Degos F; Saimot AG, Erlinger S;
Benhamou JP. Recombinant interferon-alpha for chronic hepatitis C in patients
positive for antibody to human immunodeficiency virus. Comite des Anti-
Viraux. J Infect Dis 1992;165:723-6 105.McMahon BJ, Alberts SR, Wainwright RB, Bulkow L. Lanier AP. Hepatitis
B related sequelae. Prospective study of 1400 hepatitis B surface antigen
positive Alaskan native carriers. Arch Intern Med 1990; 150: 1051-1054. 106.Villeneuve JP; Desrochers M; Infante-Rivard C, Willems B; Raymond
G; Bourcier M et al. A long-term follow-up study of asymptomatic hepatitis
B surface antigen- positive carriers in Montreal. Gastroenterology 1994;106:1000-5 107.Sherman M, Peltekian KM; Lee C. Screening for hepatocellular carcinoma
in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular
carcinoma in a North American urban population. Hepatology. 1995;22:432-8. 108.Okuda K, Ohtsuki T; Obata H; Tomimatsu M; Okazaki N; Hasegawa H
et al. Natural history of hepatocellular carcinoma and prognosis in relation
to treatment. Study of 850 patients. Cancer. 1985;56:918-28. 109.Heyward WL, Lanier AP; McMahon BJ; Fitzgerald MA; Kilkenny S; Paprocki
TR. Early detection of primary hepatocellular carcinoma. Screening for
primary hepatocellular carcinoma among persons infected with hepatitis
B virus. JAMA. 1985;254:3052-4. 110.Franks AL, Berg CJ; Kane MA; Browne BB; Sikes RK; Elsea WR; Burton
AH. Hepatitis B virus infection among children born in the United States
to Southeast Asian refugees. N Engl J Med. 1989;321(19):1301-5. 111.Hurie MB, Mast EE; Davis JP. Horizontal transmission of hepatitis
B virus infection to United States-born children of Hmong refugees. Pediatrics.
1992;89:269-73. 112.Mahoney FJ, Lawrence M; Scott C; Le Q; Lambert S; Farley TA Continuing
risk for hepatitis B virus transmission among Southeast Asian infants in
Louisiana. Pediatrics. 1995;96:1113-6. 113.Prevention of Transmission of hepatitis B. Can Med Assoc J. 1998
159:71-6. 114.Vento S, Garofano T; Renzini C; Cainelli F; Casali F; Ghironzi G.
Fulminant hepatitis associated with hepatitis A virus superinfection in
patients with chronic hepatitis C. N Engl J Med. 1998;338:286-90. 115.Keeffe EB; Iwarson S; McMahon BJ; Lindsay KL; Koff RS; Manns M;
et al. Safety and immunogenicity of hepatitis A vaccine in patients with
chronic liver disease. Hepatology 1998 27:881-6 116.Preventing hepatitis A infections. National Advisory Committee on
Immunization statement. Laboratory Centre for Disease Control. Can Fam
Physician 1995 41:1222-8 117.Linnen J; Wages J Jr; Zhang-Keck ZY; Fry KE Krawczynski KZ; Alter
H et al. Molecular cloning and disease association of hepatitis G virus:
a transfusion-transmissible agent. Science 1996;271(5248):505-8 118.Alter HJ; Nakatsuji Y; Melpolder J; Wages J Wesley R; Shih JW; Kim
JP. The incidence of transfusion-associated hepatitis G virus infection
and its relation to liver disease. N Engl J Med 1997;336:747-54 119.Alter MJ; Gallagher M; Morris TT; Moyer LA; Meeks EL Krawczynski
K et al. Acute non-A-E hepatitis in the United States and the role of hepatitis
G virus infection. Sentinel Counties Viral Hepatitis Study Team. N Engl
J Med 1997;336:741-6 120.Frider B, Sookoian S, Castano G, Gonzalez J, Flichman D, Viudez
P et al.. Detection of hepatitis G virus RNA in patients with acute non-A-E
hepatitis. J Viral Hepat 1998;5:161-4 121.Pessoa MG; Terrault NA; Detmer J; Kolberg J Collins M; Hassoba HM;
Wright TL. Quantitation of hepatitis G and C viruses in the liver: evidence
that hepatitis G virus is not hepatotropic. Hepatology 1998;27:877-80 122.Berenguer M, Terrault NA; Piatak M; Yun A; Kim JP; Lau JY et al.
Hepatitis G virus infection in patients with hepatitis C virus infection
undergoing liver transplantation. Gastroenterology. 1996;111:1569-75. 123.Naoumov NV, Petrova EP, Thomas MG, Williams R. Presence of a newly
described human DNA virus (TTV) in patients with liver disease. Lancet
1998,352:195-97 124.Simmonds P, Davidson F, Lycett C, Prescott LE, MacDonald DM, Ellender
J et al. Detection of a novel DNA virus (TTV) in blood donors and blood
products. Lancet 1998 352:191-5 125.Hsieh Sy, Wu YH, Ho YP, Tsao KC, Yeh CT, Liaw YF. High prevalence
of TT virus infection in healthy children and adults and in patients with
liver disease in Taiwan.
.
80.Davis GL; Esteban-Mur R; Rustgi V; Hoefs J; Gordon SC; Trepo C et
al. Interferon alfa-2b alone or in combination with ribavirin for the treatment
of relapse of chronic hepatitis C. International Hepatitis Interventional
Therapy Group. . N Engl J Med 1998 339:1493-9